Literature DB >> 6275447

Excitatory and depressant effects of delta 9-tetrahydrocannabinol and cannabidiol on cortical evoked responses in the conscious rat.

S A Turkanis, R Karler.   

Abstract

The influences of delta 9-tetrahydrocannabinol (THC) and cannabidiol on electrically evoked cortical potentials of conscious rats with chronically implanted electrodes were investigated. Specifically, the cannabinoids' effects on a transcallosal evoked response were compared with those of ethosuximide, phenytoin, and pentylenetetrazol. THC produced dose-related opposite effects: Low doses increased the amplitude of the response, whereas higher doses reduced the response. Other drugs that can cause or exacerbate seizures, i. e., phenytoin and pentylenetetrazol, also increased the amplitude of the cortical response. In contrast, cannabidiol, over a wide dosage range, caused only depression. Ethosuximide, like cannabidiol, elicited a depressant effect. The data indicate that under the conditions of the present investigation, cannabidiol shares electrophysiological properties with ethosuximide but not with phenytoin, and that cannabidiol is a relatively selective, centrally acting drug. In addition, our findings support the suggestion that augmentation of neurotransmission in central pathways may contribute to the convulsant actions of THC, and the cannabinoids' depressant effects may, at least partially, account for their anticonvulsant actions.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6275447     DOI: 10.1007/bf00432442

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  Effects of diphenylhydantoin on synaptic transmission in cat spinal cord and stellate ganglion.

Authors:  D W ESPLIN
Journal:  J Pharmacol Exp Ther       Date:  1957-07       Impact factor: 4.030

2.  Kindling, unit discharge patterns and neural plasticity.

Authors:  R Racine; L Tuff; J Zaide
Journal:  Can J Neurol Sci       Date:  1975-11       Impact factor: 2.104

Review 3.  Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of delta9-tetrahydrocannabinol.

Authors:  L E Hollister
Journal:  Pharmacology       Date:  1974       Impact factor: 2.547

4.  The effects of some anticonvulsant drugs on cobalt-induced epilepsy.

Authors:  R C Dow; J C Forfar; J K McQueen
Journal:  Epilepsia       Date:  1973-06       Impact factor: 5.864

5.  Anticonvulsant properties of cannabidiol.

Authors:  S A Turkanis; W Cely; D M Olsen; R Karler
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1974-06

6.  A comparison of the pharmacological activity in man of intravenously administered delta9-tetrahydrocannabinol, cannabinol, and cannabidiol.

Authors:  M Perez-Reyes; M C Timmons; K H Davis; E M Wall
Journal:  Experientia       Date:  1973-11-15

7.  Cannabinoid-induced enhancement and depression of cat monosynaptic reflexes.

Authors:  A Tramposch; C Sangdee; D N Franz; R Karler; S A Turkanis
Journal:  Neuropharmacology       Date:  1981-06       Impact factor: 5.250

8.  Electroencephalogram and somatosensory evoked potential changes after administration of six convulsant drugs.

Authors:  B J Kaplan; P D Williamson
Journal:  Exp Neurol       Date:  1978-03       Impact factor: 5.330

9.  The effects of some drugs on an evoked response sensitive to tetrahydrocannabinols.

Authors:  E S Boyd; E H Boyd; L E Brown
Journal:  J Pharmacol Exp Ther       Date:  1974-06       Impact factor: 4.030

10.  Effects of tetrahydrocannabinols on kindled amygdaloid seizures and photogenic seizures in Senegalese baboons, Papio papio.

Authors:  J A Wada; T Osawa; M E Corcoran
Journal:  Epilepsia       Date:  1975-09       Impact factor: 5.864

View more
  3 in total

1.  Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action.

Authors:  Eleni T Tzavara; Mark Wade; George G Nomikos
Journal:  J Neurosci       Date:  2003-10-15       Impact factor: 6.167

2.  Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Authors:  Brenda E Porter; Catherine Jacobson
Journal:  Epilepsy Behav       Date:  2013-12       Impact factor: 2.937

Review 3.  Cannabinoid-Induced Hyperemesis: A Conundrum-From Clinical Recognition to Basic Science Mechanisms.

Authors:  Nissar A Darmani
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.